Winters A L, Baggett D W, Lee J D, Sloan G L, Lemmon R D, Stinson R S
Dev Biol Stand. 1985;61:233-40.
Treatment of mice by intraperitoneal inoculation of pertussis vaccine or lipopolysaccharide extracted from B. pertussis will effect resistance to rabies virus, encephalomyocarditis virus, Semliki Forest virus, and Herpes simplex virus. Our previous observations indicated that treatment of C3H/HeN (+/nu) and BDF1 mice with pertussis vaccine injected i.p. five days prior to a mouse adenovirus lethal dose i.p. challenge elicited resistance to clinical disease and death. Susceptibility returned to a portion of the test population 35 days after pertussis vaccine treatment. The pertussis vaccine induced resistance developed in athymic (nude) mice also; however, the population succumbed to infection 35 days later. Titration of pertussis vaccine with respect to induction of resistance indicated the median effective dose (ED50) was approximately 25 micrograms dry weight. This report describes the antiviral activity of acellular components extracted from pertussis vaccine. Extraction of B. pertussis cells with 1.0M NaCl and ammonium sulfate fractionation (20-40% saturation) of the extract resulted in an acellular preparation that induced resistance to lethal dose mouse adenovirus infection. The resistance inducing activity was retained after treatment of the extract with detergent (GAF Emulphogene BC 720) to remove lipopolysaccharide and adsorption to alum gel. Comparison of endotoxin content of pertussis vaccine acellular fractions, polysaccharide fraction and purified lipopolysaccharide suggested that endotoxin probably plays a role in the induction of resistance. The endotoxin content of a Emulphogene-treated preparation that protected 80% of a test population was 39 ng. The lipopolysaccharide extracted from Escherichia coli, Vibrio cholerae, Salmonella typhimurium, and Salmonella minnesota did not induce a resistant state seven days after administration; however, lipopolysaccharide extracted from B. pertussis induced a resistant state.(ABSTRACT TRUNCATED AT 250 WORDS)
通过腹腔接种百日咳疫苗或从百日咳博德特氏菌中提取的脂多糖来处理小鼠,会影响其对狂犬病病毒、脑心肌炎病毒、塞姆利基森林病毒和单纯疱疹病毒的抵抗力。我们之前的观察表明,在腹腔注射致死剂量的小鼠腺病毒进行攻击前五天,对C3H/HeN(+/nu)和BDF1小鼠腹腔注射百日咳疫苗进行处理,可使其对临床疾病和死亡产生抵抗力。在百日咳疫苗处理35天后,部分受试群体的易感性恢复。百日咳疫苗诱导的抵抗力在无胸腺(裸)小鼠中也会产生;然而,该群体在35天后会死于感染。对百日咳疫苗诱导抵抗力的滴定表明,中位有效剂量(ED50)约为25微克干重。本报告描述了从百日咳疫苗中提取的无细胞成分的抗病毒活性。用1.0M氯化钠提取百日咳博德特氏菌细胞,并对提取物进行硫酸铵分级分离(20 - 40%饱和度),得到一种无细胞制剂,该制剂可诱导对致死剂量小鼠腺病毒感染的抵抗力。在用去污剂(GAF Emulphogene BC 720)处理提取物以去除脂多糖并吸附到明矾凝胶后,诱导抵抗力的活性得以保留。对百日咳疫苗无细胞组分、多糖组分和纯化脂多糖的内毒素含量进行比较表明,内毒素可能在抵抗力的诱导中起作用。一种能保护80%受试群体的经Emulphogene处理的制剂的内毒素含量为39纳克。从大肠杆菌、霍乱弧菌、鼠伤寒沙门氏菌和明尼苏达沙门氏菌中提取的脂多糖在给药七天后未诱导出抵抗状态;然而,从百日咳博德特氏菌中提取的脂多糖可诱导出抵抗状态。(摘要截短于250字)